DaVita Inc. (DVA)

DaVita Inc. is trading at $177.69, up 0.56% on the session. The 50 day average sits at $213.51 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 26.2, which reads as oversold, and MACD is bearish crossover. Volume is below average.

The nearest support is around $176.59 with resistance near $199.15, so that band frames the current range. Average daily movement is roughly $8.18, or about 4.6% of the share price, which is what any stop placement has to allow for. The overall health score of 41 out of 100 combines a trend score of 44, momentum of 28 and a risk score of 54.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.